230 related articles for article (PubMed ID: 32787454)
1. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC
Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454
[No Abstract] [Full Text] [Related]
2. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.
Takakusagi Y; Kishimoto S; Naz S; Matsumoto S; Saito K; Hart CP; Mitchell JB; Krishna MC
Antioxid Redox Signal; 2018 Jan; 28(2):131-140. PubMed ID: 28741367
[TBL] [Abstract][Full Text] [Related]
3. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
Liapis V; Zinonos I; Labrinidis A; Hay S; Ponomarev V; Panagopoulos V; Zysk A; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
Cancer Med; 2016 Mar; 5(3):534-45. PubMed ID: 26749324
[TBL] [Abstract][Full Text] [Related]
4. Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature and Inhibition of Homologous Recombination DNA Repair.
Otowa Y; Kishimoto S; Saida Y; Yamashita K; Yamamoto K; Chandramouli GVR; Devasahayam N; Mitchell JB; Krishna MC; Brender JR
Antioxid Redox Signal; 2023 Sep; 39(7-9):432-444. PubMed ID: 37051681
[No Abstract] [Full Text] [Related]
5. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
Liapis V; Zysk A; DeNichilo M; Zinonos I; Hay S; Panagopoulos V; Shoubridge A; Difelice C; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
Cancer Med; 2017 Sep; 6(9):2164-2176. PubMed ID: 28799237
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L
Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490
[TBL] [Abstract][Full Text] [Related]
7. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
[TBL] [Abstract][Full Text] [Related]
8. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
Takakusagi Y; Matsumoto S; Saito K; Matsuo M; Kishimoto S; Wojtkowiak JW; DeGraff W; Kesarwala AH; Choudhuri R; Devasahayam N; Subramanian S; Munasinghe JP; Gillies RJ; Mitchell JB; Hart CP; Krishna MC
PLoS One; 2014; 9(9):e107995. PubMed ID: 25254649
[TBL] [Abstract][Full Text] [Related]
9. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
Bailey KM; Cornnell HH; Ibrahim-Hashim A; Wojtkowiak JW; Hart CP; Zhang X; Leos R; Martinez GV; Baker AF; Gillies RJ
PLoS One; 2014; 9(12):e113586. PubMed ID: 25532146
[TBL] [Abstract][Full Text] [Related]
12. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts.
Zhang X; Wojtkowiak JW; Martinez GV; Cornnell HH; Hart CP; Baker AF; Gillies R
PLoS One; 2016; 11(5):e0155289. PubMed ID: 27227903
[TBL] [Abstract][Full Text] [Related]
13. Evofosfamide, a new horizon in the treatment of pancreatic cancer.
Pourmorteza M; Rahman ZU; Young M
Anticancer Drugs; 2016 Sep; 27(8):723-5. PubMed ID: 27232101
[TBL] [Abstract][Full Text] [Related]
14. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
Sun JD; Liu Q; Ahluwalia D; Li W; Meng F; Wang Y; Bhupathi D; Ruprell AS; Hart CP
Cancer Biol Ther; 2015; 16(3):438-49. PubMed ID: 25679067
[TBL] [Abstract][Full Text] [Related]
16. Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma.
Jardim-Perassi BV; Mu W; Huang S; Tomaszewski MR; Poleszczuk J; Abdalah MA; Budzevich MM; Dominguez-Viqueira W; Reed DR; Bui MM; Johnson JO; Martinez GV; Gillies RJ
Theranostics; 2021; 11(11):5313-5329. PubMed ID: 33859749
[No Abstract] [Full Text] [Related]
17. Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer.
Yoon J; Kang SY; Lee KH; Cheon GJ; Oh DY
Cancer Res Treat; 2021 Apr; 53(2):471-479. PubMed ID: 33091966
[TBL] [Abstract][Full Text] [Related]
18. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
Hong CR; Wilson WR; Hicks KO
Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation-An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302.
Saggar JK; Tannock IF
Clin Cancer Res; 2015 May; 21(9):2107-14. PubMed ID: 25677696
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P
BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
